Proton and 31-phosphorus neurospectroscopy in the study of membrane phospholipids and fatty acid intervention in schizophrenia, depression, chronic fatigue syndrome (myalgic encephalomyelitis) and dyslexia. — CFSMEATLAS
Proton and 31-phosphorus neurospectroscopy in the study of membrane phospholipids and fatty acid intervention in schizophrenia, depression, chronic fatigue syndrome (myalgic encephalomyelitis) and dyslexia.
Puri, Basant K · International review of psychiatry (Abingdon, England) · 2006 · DOI
Quick Summary
This study describes advanced brain imaging techniques that can measure specific chemicals in the brain without surgery. These techniques help researchers understand how the brain uses fats and other building blocks to maintain healthy cell membranes. The authors explain how these imaging methods could be applied to study brain chemistry in ME/CFS and other conditions.
Why It Matters
This study is significant because it outlines non-invasive neuroimaging methods that could reveal underlying brain chemistry abnormalities in ME/CFS. Understanding abnormal membrane phospholipid metabolism could provide biological markers for the disease and guide development of targeted treatments, particularly fatty acid interventions. These techniques offer potential for objectively studying brain-based mechanisms in ME/CFS.
Observed Findings
Proton spectroscopy can measure brain choline, glutamate, glutamine, creatine, and N-acetyl aspartate at 1.5T magnetic field strength or higher.
31-phosphorus spectroscopy can measure phosphomonoesters, inorganic phosphate, phosphodiesters, phosphocreatine, and ATP resonances.
Elevated free choline may reflect decreased synthesis of membrane phospholipid molecules.
Phosphomonoesters primarily include phosphocholine, phosphoethanolamine, and phosphoserine (precursors of membrane phospholipids).
Phosphodiesters primarily include glycerophosphocholine and glycerophosphoethanolamine (products of membrane phospholipid breakdown).
Inferred Conclusions
Proton and 31-phosphorus neurospectroscopy provide complementary non-invasive methods to assess cerebral membrane phospholipid metabolism.
Abnormal patterns in choline-containing compounds and phosphomonoester/phosphodiester ratios could indicate membrane phospholipid dysfunction in ME/CFS and related conditions.
These imaging techniques could be applied to investigate whether membrane phospholipid metabolism is abnormal in ME/CFS and to monitor responses to fatty acid interventions.
Remaining Questions
Do ME/CFS patients actually show abnormal neurospectroscopic patterns compared to healthy controls?
What This Study Does Not Prove
This review article does not provide empirical evidence that membrane phospholipid abnormalities actually exist in ME/CFS patients—it only proposes that the imaging techniques could detect such abnormalities if present. It does not demonstrate causation between any biochemical changes and ME/CFS symptoms. The study does not compare ME/CFS patients to healthy controls or show that fatty acid interventions improve outcomes.